Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity

  1. Shuaijie Dou
  2. Guoxian Li
  3. Ge Li
  4. Chunmei Hou
  5. Yang Zheng
  6. Lili Tang
  7. Yang Gao
  8. Rongliang Mo
  9. Yuxiang Li
  10. Renxi Wang  Is a corresponding author
  11. Beifen Shen
  12. Jun Zhang  Is a corresponding author
  13. Gencheng Han  Is a corresponding author
  1. Beijing Institute of Basic and Medical Sciences, China
  2. First hospital of Jilin University, China
  3. Beijing Institute of Basic Medical Sciences, China
  4. Medical School of Henan University,, China

Abstract

Nuclear Factor 90 (NF90) is a novel virus sensor that serves to initiate antiviral innate immunity by triggering the stress granules (SGs) formation. However, the regulation of the NF90-SGs pathway remain largely unclear. We found that Tim-3, an immune checkpoint inhibitor, promotes the ubiquitination and degradation of NF90 and inhibits NF90-SGs mediated antiviral immunity. Vesicular Stomatitis Virus (VSV) infection induces the up-regulation and activation of Tim-3 in macrophages which in turn recruited the E3 ubiquitin ligase TRIM47 to the zinc finger domain of NF90 and initiated a proteasome-dependent degradation via K48-linked ubiquitination at Lys297. Targeted inactivation of the Tim-3 enhances the NF90 downstream SGs formation by selectively increasing the phosphorylation of PKR and eIF2a, the expression of SGs markers G3BP1 and TIA-1, and protected mice from VSV challenge. These findings provide insights into the crosstalk between Tim-3 and other receptors in antiviral innate immunity and its related clinical significance.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Shuaijie Dou

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  2. Guoxian Li

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  3. Ge Li

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  4. Chunmei Hou

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  5. Yang Zheng

    4.Department of Oncology,, First hospital of Jilin University, Department of Oncology,, China
    Competing interests
    The authors declare that no competing interests exist.
  6. Lili Tang

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  7. Yang Gao

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  8. Rongliang Mo

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  9. Yuxiang Li

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  10. Renxi Wang

    Laboratory of Immunology, Beijing Institute of Basic Medical Sciences, Beijing, China
    For correspondence
    wang_renxi@hotmail.com
    Competing interests
    The authors declare that no competing interests exist.
  11. Beifen Shen

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    Competing interests
    The authors declare that no competing interests exist.
  12. Jun Zhang

    Institute of Immunology,, Medical School of Henan University,, Kaifeng, China
    For correspondence
    zhangjun@henu.edu.cn
    Competing interests
    The authors declare that no competing interests exist.
  13. Gencheng Han

    Immunology, Beijing Institute of Basic and Medical Sciences, Beijing, China
    For correspondence
    genchenghan@163.com
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1408-878X

Funding

This work was supported by the National Natural Sciences Foundation of China (grants no. 81971473, 81771684), and the Beijing Natural Sciences Foundation (grant no.7192145).

Ethics

Animal experimentation: The protocol was approved by the Ethics Committee of Animal Experiments of the Beijing Institute of Brain Sciences( (IACUC-DWZX-2018-645). All efforts were made to minimize suffering.

Copyright

© 2021, Dou et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 905
    views
  • 191
    downloads
  • 16
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Shuaijie Dou
  2. Guoxian Li
  3. Ge Li
  4. Chunmei Hou
  5. Yang Zheng
  6. Lili Tang
  7. Yang Gao
  8. Rongliang Mo
  9. Yuxiang Li
  10. Renxi Wang
  11. Beifen Shen
  12. Jun Zhang
  13. Gencheng Han
(2021)
Ubiquitination and degradation of NF90 by Tim-3 inhibits antiviral innate immunity
eLife 10:e66501.
https://doi.org/10.7554/eLife.66501

Share this article

https://doi.org/10.7554/eLife.66501

Further reading

    1. Immunology and Inflammation
    Weigao Zhang, Hu Liu ... Dan Weng
    Research Article

    As a central hub for metabolism, the liver exhibits strong adaptability to maintain homeostasis in response to food fluctuations throughout evolution. However, the mechanisms governing this resilience remain incompletely understood. In this study, we identified Receptor interacting protein kinase 1 (RIPK1) in hepatocytes as a critical regulator in preserving hepatic homeostasis during metabolic challenges, such as short-term fasting or high-fat dieting. Our results demonstrated that hepatocyte-specific deficiency of RIPK1 sensitized the liver to short-term fasting-induced liver injury and hepatocyte apoptosis in both male and female mice. Despite being a common physiological stressor that typically does not induce liver inflammation, short-term fasting triggered hepatic inflammation and compensatory proliferation in hepatocyte-specific RIPK1-deficient (Ripk1-hepKO) mice. Transcriptomic analysis revealed that short-term fasting oriented the hepatic microenvironment into an inflammatory state in Ripk1-hepKO mice, with up-regulated expression of inflammation and immune cell recruitment-associated genes. Single-cell RNA sequencing further confirmed the altered cellular composition in the liver of Ripk1-hepKO mice during fasting, highlighting the increased recruitment of macrophages to the liver. Mechanically, our results indicated that ER stress was involved in fasting-induced liver injury in Ripk1-hepKO mice. Overall, our findings revealed the role of RIPK1 in maintaining liver homeostasis during metabolic fluctuations and shed light on the intricate interplay between cell death, inflammation, and metabolism.

    1. Immunology and Inflammation
    Shih-Wen Huang, Yein-Gei Lai ... Nan-Shih Liao
    Research Article

    Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I+ breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3-CD4+ T cells and stem cell-like CD8+ T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I+ tumor cells by activating the cDC-T cell axis at metastatic sites.